Celecoxib but Not Rofecoxib Inhibits the Growth of Transformed Cells in Vitro

Clinical Cancer Research

Volumn 10, Issue 1 I, 2004, Pages 267-271

  Kazanov, Diana ^a   Dvory Sobol, Hadas ^a   Pick, Marjorie ^a   Liberman, Eliezer ^a   Strier, Ludmila ^a   Choen Noyman, Efrat ^a   Deutsch, Varda ^a   Kunik, Talya ^a   Arber, Nadir ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CELECOXIB; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ANIMAL CELL; APOPTOSIS; ARACHIDONIC ACID METABOLISM; ARTICLE; CARCINOGENESIS; CELL CULTURE; CELL GROWTH; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; INTESTINE CELL; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 8; CASPASES; CELL CYCLE; CELL LINE, TRANSFORMED; CYCLOOXYGENASE INHIBITORS; ENTEROCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENES, RAS; LACTONES; PYRAZOLES; RATS; SULFONAMIDES; SULFONES;

EID: 1642453728     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0412-3     Document Type: Article

References (28)

1. Parkin, D. M., Pisani, P., and Ferlay, J. Global cancer statistics. CA - Cancer J. Clin., 49: 33-64, 1999.
2. Peeters, M., and Haller, D. G. Therapy for early stage colorectal cancer. Oncology, 13: 307-315, 1999.
3. Cole, P., and Sateren, W. The evolving picture of cancer in America. J. Natl. Cancer Inst. (Bethesda), 87: 159-160, 1995.
4. Strul, H., and Arber, N. NSAIDs prevent colorectal cancer: the role of the super aspirins. Isr. Med. Assoc. J., 2: 322-324, 2000.
5. DuBois, R. N., Giardiello, F. M., and Sammalley, W. E. NSAIDs, eicosanoids, and colorectal cancer prevention. Gastroenterol. Clin. N. Am., 25: 773-791, 1996.
6. Muscat, J. E., Stellman, S. D., and Wynder, E. L. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer (Phila.), 74: 1847-1854, 1994.
7. Wolfe, M. M., Lichtenstein, D. R., and Singh, G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med., 340: 1888-1899, 1999.
8. Hla, T., and Neilson, K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA, 89: 7384-7388, 1992.
9. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., and DuBois, R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 1183-1188, 1994.
10. Reddy, B. S., Rao, C. V., and Seibert, K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res., 56: 4566-4571, 1996.
11. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in APC knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
12. Jacoby, R. F., Seibert, K., Cole, C. E., Kelloff, G., and Lubet, R. A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res., 60: 5040-5044, 2000.
13. Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res., 61: 1733-1740, 2001.
14. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., and Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342: 1946-1952, 2000.
15. Hallak, A., Alon-Baron, L., Shamir, R., Moshkowitz, M., Bulvik, B., Brazowski, E., Halpern, Z., and Arber, N. Rofecoxib reduces polyp recurrence in familial polyposis. Dig. Dis. Sci., 48: 1998-2002, 2003.
16. Arber, N., Deutsch, V., Pick, M., Kaznov, D., Rattan, J., Moskowitz, M., and Halpern, Z. Ras-transformed enterocytes overexpressing bak have an increased apoptotic tendency. Gastroenterology, 116: A372, 1999.
17. Arber, N., Sutter, T., Miyake, M., Kahn, S., Venkatraj, V. S., Sobrino, A., Warburton, D., Holt, P. R., and Weinstein, I. B. Increased expression of cyclin D1 and the Rb tumor suppressor gene in c-K-ras transformed rat enterocytes. Oncogene, 12: 1903-1908, 1996.
18. Kaznov, D., Stern, B., Pick, M., Deutsch, V. R., Brazowski, E., Shapira, I., et al. Down-regulation of bak expression in normal enterocytes by antisense construct results in malignant transformation. Gastroentrology, 119: A442, 2000.
19. Quaroni, A., and Isselbacher, K. J. Cytotoxic effects and metabolism of benzo(a)pyrene and 7,12-dimethylbenz(a)anthracene in duodenal and ileal epithelial cell cultures. J. Natl. Cancer Inst. (Bethesda), 67: 1353-1362, 1981.
20. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., Schnitzer, T. J., and VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med., 343: 1520-1528, 2000.
21. Deeks, J. J., Smith, L. A., and Bradley, M. D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. BMJ, 325: 607-608, 2002.
22. Hsu, A. L., Ching, T. T., Wang, D. S., Song, X., Rangnekar, V. M., and Chen, C. S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem., 275: 11397-11403, 2000.
23. Johnson, A. J., song, X., Hsu, A., and Chen, C. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv. Enzyme Regul., 41: 221-235, 2001.
24. Kusunoki, N., Yamazaki, R., and Kawai, S. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum., 46: 3159-3167, 2002.
25. Waskewich, C., Blumenthal, R. D., Li, H., Stein, R., Goldenberg, D. M., and Burton, J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res., 62: 2029-2033, 2002.
26. Averbuch, M., Kazanov, D., Pick, M., Strier, L., Dvory-Sobol, H., Deutsch, V., Halpern, Z., and Arber, N. Rofecoxib (MK-966) does not inhibit the growth of transformed cells in vitro. Gastrointest. Oncol., 3: 71-75, 2002.
27. Zhu, J., Song, X., Lin, H. P., Young, D. C., Yan, S., Marquez, V. E., and Chen, C. S. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J. Natl. Cancer Inst. (Bethesda), 94: 1745-1757, 2002.
28. Arber, N., Han, E. K. H., Sgambato, A., Piazza, G. A., Delohery, T. M., Begemann, M., Weghorst, C. M., Kim, N. H., Pamukcu, R., Ahnen, D. J., Reed, J. C., Weinstein, I. B., and Holt, P. R. A K-ras oncogene increases resistance to sulindac sulfide induced apoptosis in rat enterocytes. Gastroenterology, 113: 1892-1900, 1997.